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Abstract
Background and Purpose: This study aimed to explore the possible association of plasma total homocysteine with carotid
plaque stability.
Methods: A cross-sectional study was conducted from 2010 to 2011. A stratified random sample of 2,919 Chinese
participants aged 40 years or older was enrolled. Plasma total homocysteine levels were measured and carotid plaques were
evaluated by ultrasonography. Logistic regression model was used to analyze the association of homocysteine levels to the
progression of carotid plaque development, while adjusting for demographics and vascular risk factors.
Results: The mean level of plasma homocysteine in the subjects was 14.9 mmol/l. Along with increase in homocysteine level,
the risk of advanced carotid plaque elevated (odds ratio = 1.28; 95% confidence interval = 1.09–1.51) after adjusting for age,
sex, and other potential confounders. Stratified by sex, higher homocysteine level was strongly associated with advanced
carotid plaque in men (OR= 1.41; 95% confidence interval = 1.17–1.70), but not in women.
Conclusion: The findings suggest that plasma level of homocysteine may be associated with advanced carotid plaque,
which constitutes high risks of stroke, in male Chinese adults.
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Introduction
Stroke is the second leading cause of preventable mortalities and
one of the leading causes of long-term disability [1]. In China,
stroke and ischemic heart disease were the leading causes of
DALYs (disability-adjusted life-year) in 2010 [2]. The medical
management of ischemic stroke becomes a heavy burden to the
modern health care system worldwide [3]. Ischemic stroke is
usually caused by acute thrombosis, which is triggered by unstable
atherosclerotic plaque instead of gradually progressive luminal
narrowing [4,5]. Previous studies already have found that
homocysteine is significantly associated with ischemic stroke [6–
12]. In 2013, the result of Northern Manhattan study (NOMAS)
presented that elevated homocysteine is independently associated
with plaque morphology and increased plaque area [13].
Accumulating studies mainly focus on relationships between
homocysteine and vascular diseases, especially cardiovascular
diseases in Caucasian population. So far, however, the relationship
between homocysteine and vulnerable carotid plaque has not been
investigated. Since unstable carotid plaque is a significant
subclinical marker of stroke risk [14,15], the main purpose of
the present study, a cross-sectional study conducted in a
community-based population in Northern China, is to analyze
the relationship between the complexity of carotid plaque and the
total plasma homocysteine level.
Methods
Study Design and Population
This study was a community-based cross-sectional study in
Chinese adults derived from a reference population of the Kailuan
Cohort Study. The subjects in the Kailuan cohort study were
enrolled from a population of 101,510 employees (81,110 males
and 20,400 females) of Kailuan (Group) Co. Ltd, a large coal mine
industry in Hebei Province, China. Standard protocols were
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described previously [16,17]. From June 2010 to June 2011, using
stratified random sampling method by age and sex, 7,000 subjects
aged $40 years were randomly selected. Among them, 5,852
signed informed consents and 5,816 individuals completed
baseline data collection. Among these 5,816 participants, 401
subjects failed to meet the following inclusion criteria and
therefore were excluded from this study: (1) No history of stroke,
transient ischemic attack at baseline by a validated questionnaire,
(2) Absence of neurologic deficits for stroke which was estimated
by experienced doctors, (3) Fasting total plasma homocysteine has
been examined. Among the 5,415 participants enrolled in the
study, 2,919 were selected for carotid plaque assessed by
ultrasonographic examination. The study was approved by the
Ethics Committees of the Kailuan General Hospital and Beijing
Tiantan Hospital. All participants signed informed consent.
Assessment of Homocysteine
Blood samples were drawn by trained phlebotomists from the
subjects after overnight fasting. The venous blood samples in tubes
containing trisodium ethylenediaminetetraacetic acid were imme-
diately placed on ice after antecubital venipuncture. Blood samples
were then centrifuged for 10 minutes at 3000 rotations per minute
at 25uC. After separation, plasma samples were used within 4
hours. Fasting plasma glucose was measured using the hexoki-
nase/glucose-6-phosphate dehydrogenase method. Total choles-
terol and triglyceride were measured enzymatically according to
the manufacturer’s instruction (interassay coefficient of variation
,10%; Mind Bioengineering Co. Ltd., Shanghai, China). All
biochemical variables were measured using an autoanalyzer
(Hitachi 747; Hitachi, Tokyo, Japan) at the central laboratory of
the Kailuan General Hospital. Hyperhomocysteinemia was
defined as plasma total homocysteine levels no less than
15 mmol/l [18].
Assessment of Carotid Plaque
Carotid plaques were evaluated to assess the complexity and
advancement by trained and certified sonographers with ultra-
sounds (Philips iU-22 ultrasound system, Philips Medical Systems,
Bothell, WA). Bilateral carotid arteries including common carotid
arteries, carotid bifurcation, internal carotid artery, external
carotid artery, were all examined with the patient in a supine
position, head turning to the contralateral side. Both sides of
carotid arteries were extensively evaluated. Carotid plaque was
defined as a focal structure encroaching into the arterial lumen of
at least 0.5 mm or 50% of the surrounding IMT value, or
demonstrated as a thickness of 1.5 mm from the intima-lumen
interface to the media adventitia interface. The carotid ultrasound
examination results were then reviewed by two independent
operators. Discrepancies between their evaluations were resolved
by consensus. In this study, advanced or complicated carotid
plaques were defined based on: (1) plaques with incomplete fibrous
cap or ulcerated plaques, according to the plaque morphology,
and (2) plaques with low-level or heterogeneous echoes, according
to the plaque echodensity. Representative ultrasound images for
different types of plaques were provided (Figure 1).
Assessment of Demographic Variables and
Cardiovascular Risk Factors
Information on demographic variables (e.g. age, sex and
previous history of diseases) was collected via a questionnaire
study. The participants were classified into two groups based on
their ages: 40–59 years old group and those aged $60 years. The
information of disease history mainly included hypertension,
diabetes mellitus and hyperlipidemia. Questionnaires were also
used to collect information on smoking history, which was
classified as ‘‘yes’’, or ‘‘no’’ according to self-reported information.
Body weights (accurate to 0.1 kg) and heights (accurate to 0.1 cm)
were measured, and the body mass indexes (BMI) were calculated.
Hypertension was defined as presence of a history of hypertension,
or using antihypertensive medication, or a SBP$140 mmHg, or a
DBP$90 mmHg. Diabetes mellitus was defined as a self-reported
history, currently treated with insulin or oral hypoglycemic agents,
or fasting blood glucose level $7.0 mmol/L (126 mg/dl). Hyper-
lipidemia was defined as a self-reported history, current use of
cholesterol lowering medicine, or total cholesterol level $
5.7 mmol/L (220 mg/dl) or triglyceride $1.7 mmol/L
(150 mg/dl). All the blood tests were done at the central
laboratory of the Kailuan hospital.
Statistical Analyses
Continuous variables were described by mean 6 standard
deviation (SD) and compared by ANOVA analysis. Categorical
variables were described as percentages and compared using Chi
Square tests. Logistic regression was used to evaluate the
relationship between level of plasma total homocysteine and
carotid plaque stability by calculating the crude odds ratio (OR)
and adjusted OR, with 95% confidence interval (CI).
The well-known and possible risk factors of stroke such as age,
sex, BMI, current smoking, alcohol use, hypertension, diabetes
mellitus and hyperlipidemia, were adjusted in the statistical
analysis. All statistical tests were 2-sided, and a significant level
was set as P,0.05. SAS (version 9.1, SAS Institute, Cary, North
Carolina, USA) software was used to perform data analyses.
Results
Characteristics and Risk Factors Associated with Carotid
Plaque Stability
Table 1 shows the distribution of baseline cohort characteristics
amongst those individuals with stable or advanced carotid plaque.
Among the 2,919 participants, the mean concentration of
homocysteine in elderly subjects ($60 years old) was
19.369.8 mmol/l, while 15.669.7 mmol/l in the middle-aged
subjects (40–59 years old). The level of plasma total homocysteine
was higher in men than that in women (19.2610.4 mmol/l versus
12.666.6 mmol/l respectively, P,0.01). By definition [18], 48.8%
of the total subjects had hyperhomocysteinemia (41.3% in male
and 7.5% in female). Advanced carotid plaque was detected in
1,517 (52%) participants. Among them, 76.1% were male. No
significant association was observed between carotid plaque and
BMI, alcohol use and hyperlipidemia.
Association between Total Homocysteine Levels and
Carotid Plaque Stability
As shown in Table 2, an association of increased levels of total
homocysteine with carotid plaque vulnerability in a mild dose-
response manner was identified. In all 3 multivariable-adjusted
models, higher levels of homocysteine were significantly associated
with the advancement of carotid plaque. The crude ORs for
advanced carotid plaque prevalence increased along with elevation
of homocysteine level. After adjusting for age, sex, smoking,
hypertension and diabetes mellitus, the association remained
evident. However, in this study, hyperhomocysteinemia was not
found to be significantly associated with the development of
advanced carotid plaque in the female participants.
Homocysteine and Carotid Plaque Stability
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Figure 1. Representative ultrasound images for different types of advanced carotid plaques in study participants. A represents
ulcerated plaque; B represents plaque with low-level echo; C represents plaque with heterogeneous echo.
doi:10.1371/journal.pone.0094935.g001
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Discussion
To our knowledge, this is the first observational cohort study to
explore the potential relationship between plasma homocysteine
levels and development of carotid plaques in a Chinese adult
population. Our data identified a significant association between
hyperhomocysteinemia and the development of advanced carotid
plaques in this population with an OR of 1.28 (95% CI: 1.09–1.51)
after adjusting for age, sex, and other vascular diseases related
confounders. Our data also indicated that hyperhomocysteinemia
could increase the risk of developing advanced carotid artery
plaques by 28% in the population aged above 40.
In healthy population, the physiological range of plasma total
homocysteine concentration is 5–15 mmol/L, and hyperhomocys-
teinemia ($15 mmol/L) is considered to be pathological [18].
Previous cohort studies such as the Northern Manhattan cohort
study, the Framingham Study and the British Regional Heart
Study all showed that elevated homocysteine increases the risk of
Table 1. Basic characteristics of participants according to the carotid plaque stability.
Overall participants characteristics (N=2919) Carotid Plaque Stability P-value
Stable (N=1402) Advanced (N=1517)
Mean age 6 SD (years) 60.1612.4 56.5611.2 63.4612.5 ,0.01
Men,% 71.4 66.2 76.1 ,0.01
Mean BMI 6 SD (kg/m2) 24.963.2 24.963.2 24.963.3 0.85
Current Smoker, % 44.5 42.6 46.3 0.05
Heavy drinker, % 14.9 14.7 15.1 0.76
Hypertension, % 59.3 54.9 63.3 ,0.01
Diabetes mellitus, % 16.3 14.8 17.7 0.03
Hyperlipidemia, % 54.2 52.6 55.7 0.09
Mean Homocysteine 6 SD (mmol/l) 17.369.9 16.369.6 18.3610.1 ,0.01
SD, standard deviation; BMI, body mass index;
doi:10.1371/journal.pone.0094935.t001
Table 2. ORs and 95%CIs for advanced carotid plaque according to homocysteine levels.
Homocysteine P-value continuous
,15 mmol/l $15 mmol/l
Crude Model OR(95%CI) Ref 1.62(1.40–1.87) ,0.01 1.02(1.01–1.03)
Model 1OR(95% CI)1 Ref 1.28(1.09–1.51) ,0.01 1.01(1.00–1.02)
Model 2OR(95% CI)2 Ref 1.28(1.09–1.51) 0.05 1.01(1.00–1.02)
Sex
Female
Model 1OR(95% CI)3 Ref 1.06(0.75–1.49) 0.73 1.01(0.98–1.03)
Model 2OR(95% CI)4 Ref 1.05(0.75–1.49) 0.77 1.00(0.98–1.03)
Male
Model 1OR(95% CI)3 Ref 1.40(1.17–1.69) ,0.01 1.01(1.00–1.02)
Model 2OR(95% CI)4 Ref 1.41(1.17–1.70) ,0.01 1.01(1.00–1.02)
Age
40–59 y
Model 1OR(95% CI)5 Ref 1.37(1.10–1.72) ,0.01 1.01(1.00–1.02)
Model 2OR(95% CI)6 Ref 1.35(1.08–1.70) ,0.01 1.01(1.00–1.02)
$60 y
Model 1OR(95% CI)5 Ref 1.26(0.99–1.60) 0.06 1.01(0.99–1.02)
Model 2OR(95% CI)6 Ref 1.28(1.01–1.62) 0.04 1.01(0.99–1.02)
OR, odds ratio; CI, confidence interval;
1Adjusted for age (year) and sex.
2Adjusted for age (year), sex, hypertension, diabetes mellitus, current smoker.
3Adjusted for age (year).
4Adjusted for age (year), hypertension, diabetes mellitus, current smoker.
5Adjusted for sex.
6Adjusted for sex, hypertension, diabetes mellitus, current smoker.
doi:10.1371/journal.pone.0094935.t002
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stroke [8,11,19]. Our results also suggest that carotid plaque
development is associated with level of homocysteine, which may
be indicative of the increased risk of stroke. In other words,
formation of plaques in carotid artery walls can be an important
risk factor for ischemic strokes [20]. It is widely accepted that
about 60% vascular events are caused by rupture of vulnerable
plaques that contain a large, thrombogenic core of lipid and
necrotic debris [20].
Homocysteine is an amio acid in the plasma and plays an active
role in oxide metabolism. It can also cause atherogenesis by
impairing the inner vascular wall through different mechanisms,
including damaging endothelial cells, enhancing platelet aggrega-
tion, reducing nitric oxide availability, promoting vascular smooth
muscle cell proliferation, disturbing collagen synthesis, inducing
chronic inflammation, or disrupting cholesterol and triglyceride
biosynthesis [21–28]. Consequently, impairment of vascular wall
may lead to breakdown of the integrity of the normal metabolism
cycle, which could possibly change the plasma homocysteine
concentration. Our results suggest that hyperhomocysteinemia can
represent a sensitive predictor for carotid plaque development,
particularly for the development of the advanced, unstable plaques
in males. Future laboratory research is warranted to identify the
biological involvement of homocysteine in plaque development
and vascular injuries.
Nearly 50% participants in this study with carotid plaques had
higher plasma homocysteine levels. Among those subjects with
asymptomatic carotid plaques, their plasma homocysteine levels
with vulnerable carotid plaques were much higher than in those
with stable carotid plaques. Similarly, the NOMAS showed that
elevated levels of homocysteine are independently associated with
both echolucent, low-density plaques with low content of
calcification and echodense and high-density plaques with high
content of calcification [29]. Previous studies have shown that age
and sex are the major determinants of concentration of plasma
total homocysteine [30,31]. Our study reported similar findings.
We also found that the females had lower level of homocysteine as
comparing to males. This could be due to the higher transmeth-
ylation rate in women [32]. Higher cigarettes consumption in men
might be another contributing factor for the difference between
male and female participants, which is consistent the findings from
a study in Japan [30]. However, we could not exclude the fact that
fewer female participants were enrolled than male participants in
this study, and consequently the statistic power of the result found
in females was weaker than in males. Thus, the analyses were
further stratified by gender and age, respectively. Hyperhomocys-
teinemia in the male subjects were strongly related to risk of
advanced carotid artery plaques, a phenomena that was not
observed in the female subjects. In regard to risk of age, both
middle-aged and elderly subjects with hyperhomocysteinemia
demonstrated susceptibility to development of carotid plaque, and
the ORs in subjects aged between 40–59 year old was slightly
higher than the elderly subjects. Mechanisms need to be further
explored in future studies.
Higher levels of homocysteine may be an independent risk
factor of unstable carotid plaques. It is therefore speculated that
strategies for reducing the plasma homocysteine levels in the
middle-aged male population might be useful for stroke preven-
tion. Several large clinical trials, however, did not support the use
of folic acid and vitamin B supplements for prevention of recurrent
stroke and transient ischemic attacks [33,34]. Since homocysteine
is influenced by nutritional status and genetic factors, difference in
homocysteine levels between subjects in our study and other
reports with Caucasians may be related to the different dietary
habits or genetic backgrounds. Of note, the mean age of the
studied populations in VISP [Vitamin Intervention for Stroke
Prevention] and VITATOPS [VITAmins TO Prevent Stroke]
trials were both over 65 years old [33,34]. Another study suggests
that in 66–69 years old population, homocysteine may not have a
significant association with stroke occurrence [12].
In addition to the discoveries we have made in this study, the
work had a few limitations. This is a cross-sectional study, which
limits our ability to interpret the elevation of homocysteine level as
a consequence or a causative factor of the development of carotid
plaque. Also, we did not measure the plasma concentrations of
serum folate and vitamin B12, which might affect the homocysteine
level and potentially cause the bias. Further cohort studies are
needed to further investigate these questions.
Conclusion
In conclusion, the findings in this study show that higher level of
total plasma homocysteine may be an independent risk factor for
carotid plaque development in male Chinese adults. More
epidemiological and experimental investigations are needed to
explore whether increased homocysteine level plays a causative
role in the advancement of advanced carotid plaque.
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